Dermatology and Therapy最新文献

{"title":"Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities.","authors":"Victoria Barbosa, Tina Bhutani-Jacques, Valerie D Callender, Elizabeth D Bacci, Evangeline Pierce, Beth Mitchell, Julia R Correll, Nicole Huang","doi":"10.1007/s13555-026-01851-6","DOIUrl":"10.1007/s13555-026-01851-6","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis, a chronic immune-mediated inflammatory skin condition with systemic implications and substantial psychosocial burden, affects individuals across races and ethnicities. This study explored social drivers of health (SDOH), disease burden, and the impact of psoriasis across races and ethnicities.</p><p><strong>Methods: </strong>An online, cross-sectional survey was conducted among adult US patients with psoriasis (September-December 2023). Participants were recruited through the National Psoriasis Foundation and AmeriSpeak, a national sample panel. Descriptive data were collected using patient-reported outcome measures and questions on disease knowledge, healthcare access and utilization, quality of life (QoL), and social impact. Analyses were stratified by races and ethnicities.</p><p><strong>Results: </strong>Among 285 participants (mean age 46.7 years; 50.9% male), 68.1% identified as white, 19.3% as Black/African American (BAA), and 20.4% as Hispanic/Latino (H/L). Overall, psoriasis severity was reported as moderate by 36.8% (white: 37.6%, BAA: 25.5%, Asian: 50.0%, and H/L: 27.6%) and severe by 10.2% (white: 8.2%, BAA: 10.9%, Asian: 20.0%, and H/L: 6.9%) of patients. Participants reported moderate QoL impact (Dermatology Life Quality Index [DLQI] mean 10.3), with high burden among H/L (16.6) and BAA (15.1) groups. During flares, 58.6% used prescription medications, with similar rates across races and ethnicities. Transportation barriers were reported by 21.4% overall, more commonly reported by H/L (44.8%) and BAA (34.5%) participants. Difficulty accessing medicine/healthcare was reported by 26.3% overall, particularly white (29.4%) participants. Overall, 29.1% delayed care owing to cultural/linguistic differences, most commonly by BAA and H/L groups. Of the healthcare services requiring partial out-of-pocket payment for treatment of psoriasis, medications were reported as the highest burden by an overall 47.0% of patients (H/L: ~55%, white and BAA ~45%). Overall, only 29.5% received financial assistance.</p><p><strong>Conclusions: </strong>In this descriptive survey, patients perceived psoriasis as a considerable burden across races and ethnicities. Understanding diversities in patient-reported SDOH and healthcare access issues through culturally competent integrated care may potentially optimize psoriasis outcomes.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4433-4458"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.","authors":"Marc Hernández-Santacana, Pablo Balado-Simó, Miguel Mansilla-Polo, Josep Riera-Monroig","doi":"10.1007/s13555-026-01846-3","DOIUrl":"10.1007/s13555-026-01846-3","url":null,"abstract":"<p><p>Pediatric psoriasis is a chronic, immune-mediated inflammatory disease that frequently begins in childhood or adolescence. Beyond cutaneous involvement, it is associated with a wide spectrum of metabolic, psychological, and inflammatory comorbidities, as well as a marked impairment in health-related quality of life in both patients and their caregivers. This narrative review summarizes current evidence on comorbidities, treatment challenges, unmet needs, and future directions in pediatric psoriasis. Available data indicate an increased risk of overweight and obesity, the clustering of cardiometabolic risk factors, and a high prevalence of psychological and psychiatric comorbidities, including depression, anxiety, and suicidal ideation. Inflammatory comorbidities, particularly psoriatic arthritis, require early recognition to prevent irreversible complications. Therapeutic management of pediatric psoriasis has advanced in recent years with the approval of several biologic therapies supported by pediatric-specific clinical trials. Nevertheless, important challenges remain. These include limited access to biologics, age restrictions, off-label use of conventional systemic therapies, vaccination considerations, and scarcity of long-term safety data, particularly regarding growth, pubertal development, and cumulative drug exposure. Moreover, clear and regularly updated therapeutic algorithms for pediatric patients are still lacking. Despite increasing research activity and ongoing clinical trials, substantial unmet needs persist. These include delays in pediatric drug development, limited evidence beyond plaque psoriasis, insufficient evaluation of extracutaneous outcomes, and poor understanding of the long-term trajectory of comorbidities. Emerging data suggesting immunopathogenic differences between pediatric and adult psoriasis, together with ongoing biomarker research, may inform future personalized approaches. Addressing these gaps will be essential to optimize long-term, patient-centered care for children and adolescents with psoriasis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4249-4271"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148396198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study.","authors":"Felix Lauffer, Boris Bauer, Katharina Kreutzer, Knut Schäkel, Uwe Schwichtenberg, Johannes Hockmann, Andreas Pinter, Fatima Abousamra, Melanie Huber, Stephan Weidinger","doi":"10.1007/s13555-026-01855-2","DOIUrl":"10.1007/s13555-026-01855-2","url":null,"abstract":"<p><strong>Introduction: </strong>Minimal disease activity (MDA) has recently been introduced as comprehensive treatment target in atopic dermatitis (AD), integrating both clinician- and patient-reported outcomes. Evidence on the real-world feasibility and impact of achieving MDA on quality of life (QoL) remains limited. This analysis evaluated the association between MDA achievement and QoL outcomes in patients with moderate-to-severe AD receiving upadacitinib (UPA) in real-world clinical practice.</p><p><strong>Methods: </strong>This interim analysis used data from the ongoing, prospective, multicenter, non-interventional UP-TAINED study (NCT05139836) in Germany. Analyses included all patients without treatment interruptions during the first 12 months (n = 259). Disease control was classified as optimal, moderate, or none. Optimal control (MDA) was defined as Eczema Area and Severity Index (EASI) ≤ 3 and Worst Pruritus Numeric Rating Scale (WP-NRS) ≤ 0/1; moderate control as EASI ≤ 3 with WP-NRS 2-3 or EASI > 3-7 with WP-NRS ≤ 3; and no control as EASI > 7 or WP-NRS > 3. QoL outcomes were assessed using validated patient-reported measures.</p><p><strong>Results: </strong>MDA was achieved by 38.2% of patients at month 1 and by 42.1% at month 12. Those achieving MDA reported substantially greater improvements across all QoL measures compared with patients with moderate or no disease control. QoL outcomes were comparable between patients starting UPA at 15 mg or 30 mg. The most frequent adverse events were AD, acne, and corona virus disease 2019 (COVID-19) infection; the safety profile was consistent and no new safety signals were identified.</p><p><strong>Conclusion: </strong>Achieving MDA was associated with markedly improved QoL in real-world AD management, supporting MDA as a feasible and clinically meaningful treatment goal in routine practice.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier, NCT05139836.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4599-4616"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necrobiotic Xanthogranuloma (NXG): Dermoscopic and Reflectance Confocal Microscopic Findings and Review of Treatment with Intravenous Immunoglobulin (IVIG).","authors":"Zuzanna Pawlus, Irena Wojtowicz, Ewa Kaznowska, Adam Reich, Magdalena Żychowska","doi":"10.1007/s13555-026-01868-x","DOIUrl":"10.1007/s13555-026-01868-x","url":null,"abstract":"<p><p>Necrobiotic xanthogranuloma (NXG) is a rare, chronic non-Langerhans cell histiocytosis strongly associated with paraproteinemia and hematologic disorders. This study aims to present a clinical case of NXG, with particular emphasis on the dermoscopic and reflectance confocal microscopic (RCM) findings, and to review the literature on the efficacy of intravenous immunoglobulin (IVIG) therapy in this condition. A 58-year-old woman presented with progressive yellow-orange plaques, showing irregular vessels and hemorrhagic dots on dermoscopy. RCM displayed multiple large refractive cells and smaller cells with horseshoe-like structures, corresponding to xanthomatous histiocytes and Touton cells, respectively. Diagnostic evaluation revealed monoclonal IgG gammopathy and an indolent B cell lymphoma. Long-term treatment with IVIG combined with systemic glucocorticosteroids resulted in partial improvement. A review of 16 cases with follow-up available indicates that IVIG is a highly effective therapeutic option for NXG, often leading to rapid and significant improvement or complete remission. However, long-term responses vary, and interruption of therapy may result in disease relapse, suggesting the importance of sustained treatment. In conclusion, NXG is a multisystem disease showing several characteristics in noninvasive imaging methods. Although IVIG appears highly effective, variability in treatment response highlights the need for individualized management and for further research to better understand disease pathogenesis.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4801-4817"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148577496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel.","authors":"Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta, Margarida Gonçalo","doi":"10.1007/s13555-026-01877-w","DOIUrl":"10.1007/s13555-026-01877-w","url":null,"abstract":"","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4821-4822"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148705606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis.","authors":"Matthias Augustin, Andreas Pinter, Silvia Sabatino, Louis P Sanden, Pablo Chicharro, Esther Serra-Baldrich, Mahreen Ameen, Anthony Bewley, Walid Fakhouri, Inmaculada de la Torre, Julien Seneschal","doi":"10.1007/s13555-026-01852-5","DOIUrl":"10.1007/s13555-026-01852-5","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical data surrounding treatment patterns and reasons for discontinuation of oral systemics (OS) for the treatment of adult patients with moderate-severe atopic dermatitis (AD) remain limited. AD-REAL descriptively reports the discontinuation rates and treatment responses at week (W) 24 for patients with AD initiating new OS treatments.</p><p><strong>Methods: </strong>AD-REAL is a 12-month, multinational, observational cohort study of adult patients with moderate-to-severe AD commencing either conventional systemics (CS) or baricitinib. Other Janus kinase inhibitors (JAKis) were analyzed ad hoc. The primary objective reported the discontinuation rate of patients at W24 from baseline. Secondary objectives reported outcomes for Eczema Area and Severity index (EASI), Itch Numerical Rating Scale (NRS), and pain NRS.</p><p><strong>Results: </strong>At baseline (N = 313), patients initiated CS (N = 113), baricitinib (N = 87), and other JAKi (N = 92), with a mean EASI of 19.8, 15.8, and 16.4, respectively. At W24, the Kaplan-Meier cumulative incidence of initial treatment discontinuation was 50.8% (95% confidence interval [95% CI] 40.9, 59.8) for CS, 29.0% (95% CI 19.8, 38.8) for baricitinib, and 18.8% (95% CI 11.5, 27.5) for other JAKi. The primary reason for discontinuation of baricitinib and other JAKi was primary lack of effectiveness, while CS discontinued owing to the addition of concomitant systemic treatment, adverse events, and patient/physician decisions. Of the baricitinib and other JAKi cohorts, 81.0% and 84.2% achieved an EASI ≤ 7 score, 38.1% and 38.2% improvement in pain, and 42.0% and 38.5% improvement in itch, while 63.1%, 16.7%, and 14.3% achieved these outcomes for CS, respectively.</p><p><strong>Conclusions: </strong>In this descriptive observational cohort study, patients treated with baricitinib and other JAKi reported numerically lower discontinuation rates and numerically improved clinical outcomes than patients treated with CS. Similar to early reports of baricitinib effectiveness in treating an itch-dominant subpopulation of patients with AD, patients receiving baricitinib in clinical practice reported improved outcomes for severe itch.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4585-4598"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety.","authors":"Rocío Gil-Redondo, Juan Jimenez-Cauhe, Adrián Imbernon-Moya, Diego Buendía-Castaño, Patricia Burgos Blasco, Borja Díaz-Guimaraens, Miguel Domínguez-Santas, Ángela Hermosa-Gelbard, David Saceda-Corralo, Sergio Vañó-Galván","doi":"10.1007/s13555-026-01879-8","DOIUrl":"10.1007/s13555-026-01879-8","url":null,"abstract":"<p><strong>Introduction: </strong>Female pattern hair loss (FPHL) is a chronic, progressive condition that affects quality of life. Off-label systemic antiandrogens are increasingly used, but comparative data remain limited.</p><p><strong>Methods: </strong>To compare the effectiveness, safety, and healthcare resource utilization of spironolactone versus bicalutamide in FPHL over 24 months, we conducted a unicenter retrospective cohort study of women with FPHL treated between 2018 and 2022. The primary outcome was mean change in Sinclair grade from baseline to month 24. Secondary outcomes included ≥ 1 grade improvement, adverse events, and healthcare utilization. Linear and ordinal logistic regression models were adjusted for baseline severity.</p><p><strong>Results: </strong>A total of 187 women (median age 35 years, range 15-69 years) completed 24 months of follow-up. Both drugs produced significant Sinclair grade improvement (mean change -0.5, p < 0.001). Spironolactone (n = 128) was superior, with 54.4% achieving ≥ 1 grade improvement versus 37.3% with bicalutamide (n = 59) (p = 0.030). High-dose spironolactone (> 100 mg/day, median 130 mg/day) showed greater benefit than the maximum bicalutamide dose (50 mg/day). Adverse event rate was similar, but bicalutamide caused more laboratory abnormalities and required closer monitoring.</p><p><strong>Conclusions: </strong>Both drugs are effective systemic options. Spironolactone, particularly > 100 mg/day, demonstrated greater efficacy, comparable safety, and less monitoring, supporting its potential role as first-line systemic option.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4667-4682"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Spontaneous Urticaria (CSU) in Chinese Patients: Real-World Evidence of Disease Control and Treatment Patterns from the Urticaria Voices Study.","authors":"Zuotao Zhao, Yi Li, Tara Raftery, Nadine Chapman-Rothe, Pallavi Saraswat, Jessica McCarthy, Ravneet Kaur Kohli, Cristina Constantinescu, Angie Li, Guojiao You, Ruixin Tan, Bin Yang","doi":"10.1007/s13555-026-01856-1","DOIUrl":"10.1007/s13555-026-01856-1","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic spontaneous urticaria (CSU), characterized by recurring itchy wheals (hives) and/or angioedema lasting > 6 weeks without identifiable triggers, affects 1.29% of China's population. China ranks second globally in urticaria disability-adjusted life years (DALYs), thus understanding real-world outcomes is important. We hypothesized that, despite ongoing treatment, a substantial proportion of Chinese patients with CSU experience inadequate disease control and impaired quality of life (QoL), with gaps between their treatment expectations and perceived achievability of optimal control. This study assessed patient-reported burden, treatment patterns, and unmet needs in these patients.</p><p><strong>Methods: </strong>This was a cross-sectional study using 40-min online surveys. Patients were recruited through online panels. Eligibility included adults ≥ 18 years with physician-confirmed CSU diagnosis, actively treated. Descriptive analysis was stratified by disease control and treatment type.</p><p><strong>Results: </strong>A total of 400 patients with CSU (mean age 35.09, [SD 7.24] years; 45% female) participated; 2% reported symptom onset < 1 year pre-study, 71% between 1 and 5 years, and 27% > 5 years (mean disease duration 5.31 [SD 4.89]). On the basis of the Urticaria Control Test (UCT), 35% of participants had inadequately controlled disease (UCT < 12), whereas Patient Global Impression of Severity (PGI-S) self-assessment suggested better perceived control (92% mild/no symptoms). Most diagnoses were made by dermatologists (94%); 57% of patients reported no fixed follow‑up schedule. Among inadequately controlled patients, 90% reported sleep disturbance during exacerbations. Most patients (82%) used second-generation antihistamines; one-third used Traditional Chinese Medicine. Complete symptom control was the top treatment goal (mean importance: 8.5/10), yet only 16% believed it achievable (9% of inadequately controlled).</p><p><strong>Conclusions: </strong>One-third of treated patients with CSU reported inadequate disease control impacting QoL. The disconnect between high priority for complete control and low perceived achievability, alongside irregular follow-ups, highlights limitations in current therapies and care delivery. These findings underscore the need for more effective treatments and structured, patient-centered management pathways to optimize CSU care in China.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4459-4473"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148454951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Effects of Treatments for Anogenital Warts in Non-immunocompromised Adults: A Network Meta-analysis of Randomized Controlled Trials.","authors":"Réda Saib, Elisa Joly, Sébastien Fouere, Christian Derancourt, Babacar Tounkara, Cyril Ferdynus, Antoine Bertolotti","doi":"10.1007/s13555-026-01857-0","DOIUrl":"10.1007/s13555-026-01857-0","url":null,"abstract":"<p><strong>Introduction: </strong>International guidelines for the management of anogenital warts (AGWs) propose multiple first-line options but do not prioritize treatments based on safety or tolerability. This study aimed to compare the safety profiles of topical, systemic, and ablative treatments used for external AGWs in immunocompetent adults.</p><p><strong>Methods: </strong>A systematic review and frequentist network meta-analysis of randomized controlled trials published through August 2025 was performed. Adverse events (AEs) were classified as low-, moderate-, or high-grade local AEs (LGL, MGL, HGL) and low-grade general AEs (LGG). Relative risks were estimated using random-effects models with placebo as the reference.</p><p><strong>Results: </strong>We included 107 RCTs involving 12,423 participants. Ablative procedures were associated with higher rates of moderate-to-severe local AEs compared with topical therapies. Among topical treatments, imiquimod 5% and cidofovir cream were associated with lower rates of severe AEs, whereas podophyllotoxin was more often associated with LGL. SUCRA rankings placed topical treatments above ablative therapies in terms of tolerability. Cidofovir cream demonstrated the best safety profile, followed by imiquimod 5%.</p><p><strong>Conclusion: </strong>This network meta-analysis highlights significant differences in tolerability across AGW treatments and offers a comparative framework for patient-centered therapeutic decision-making. It also emphasizes the need for standardized AE reporting in future trials.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4325-4340"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558487/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148590887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic and Psychiatric Comorbidities in Dissecting Cellulitis of the Scalp: A Retrospective Cohort Study and Scoping Review.","authors":"Lana Salloum, Katherine Sanchez, Eliza Dewey, Samantha Gregoire, Ursula Biba, Basil Alex McIntosh, Abizairie Sanchez-Feliciano, Nora Bensellam, John S Barbieri, Arash Mostaghimi","doi":"10.1007/s13555-026-01861-4","DOIUrl":"10.1007/s13555-026-01861-4","url":null,"abstract":"<p><strong>Introduction: </strong>Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory disorder traditionally described as affecting young Black men; however, its broader epidemiology and comorbidity profile remain incompletely characterized. We aimed to evaluate demographic characteristics and systemic comorbidities associated with DCS.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients diagnosed with DCS across the Mass General Brigham network from 1 January 2015 to 1 February 2025. Demographic characteristics and comorbidities, including metabolic, psychiatric, autoimmune, and smoking history, were extracted. In parallel, a structured scoping review of PubMed was performed to identify cohort studies reporting demographic and clinical data in DCS.</p><p><strong>Results: </strong>Twenty-nine patients met inclusion criteria (89.7% male; mean age 35.9 ± 10.2 years), with diverse racial representation. Nearly half had at least one additional disorder on the follicular occlusion spectrum, and 82.8% had at least one metabolic dysfunction-associated comorbidity. Psychiatric diagnoses were present in 41.4% of patients. Seventeen published cohorts comprising 710 patients were identified. Across studies, DCS consistently demonstrated strong male predominance and heterogeneous racial distribution. Overweight or obese body mass index and metabolic comorbidities were frequently reported, while psychiatric comorbidity was underreported.</p><p><strong>Conclusions: </strong>These findings challenge the conventional characterization of DCS as a disorder primarily of Black men and instead emphasize global heterogeneity. We instead support an association of DCS with male sex, metabolic dysfunction associated comorbidities, and psychiatric comorbidities. Limitations include the retrospective design, small institutional sample size, absence of control group, use of a single database, and heterogeneity in reporting across published cohorts.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"4729-4740"},"PeriodicalIF":4.6,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13558542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}